Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University
Shanghai, China
NCT Number: NCT03296670
The study intends to evaluate the efficacy of different medicine delivering by targeted perfusion catheter in coronary administration on coronary blood flow in STEMI patients with CSFP.
Looking for future studies?
Notify MeAll sexes
Interventional
Phase 4
Shanghai, China
The goal of STEMI therapy is to successfully restore epicardial blood flow. PCI has been documented as being the most effective method for restoration of epicardial blood flow. However, stenting does not necessarily equate to epicardial blood flow; not every patient achieves TIMI 3 flow after successful PCI.
Currently, there are two main types of interventions to improve epicardial blood flow. One is the mechanical method, which included thrombus aspiration catheter and the distal protective devices. It has been confirmed that the mechanical method can effectively improve epicardial and myocardial perfusion in patient with part of large vessels and high burden thrombus. But for patients with small vessels and no obvious visual thrombus, the efficacy is not significant.
The other intervention is medicine which included GP IIb/IIIa receptor antagonist, adenosine, sodium nitroprusside, verapamil etc. Part of the drugs have some effect but the overall clinical efficacy is still not satisfied.
The study intends to use targeted perfusion catheter to deliver drug to the distal targeted blood vessels. TFG and cTFC are applied to evaluate the efficacy of treatment with Alprostadil or Nitroglycerin on coronary blood flow in STEMI patients with CSFP.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patents with myocardial infarction who have symptom onset within 12h before randomization; ECG: ≥2 mm ST-segment elevation in 2 contiguous precordial leads or ≥1 mm ST-segment elevation in 2 contiguous extremity leads ; Corrected TIMI frame counted (cTFC) measured from the final angiographic imaging after PCI exceeding 40 frames; Signed informed consent form prior to trial participation.
Exclusion criteria
Coronary artery bypass surgery (CABG) history; Failed in stents implanting; Severe heart failure; Cardiogenic shock.
alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
Nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
Time frame: One mins after PCI
TIMI Flow Grade (TFG)assesses flow in the epicardial arteries
Time frame: One mins after intracoronary medicine infusion post-PCI
TIMI Flow Grade (TFG)assesses flow in the epicardial arteries
Time frame: One mins after PCI
CTFC is a continuous measurement assessing flow in the epicardial arteries.
Time frame: One mins after intracoronary medicine infusion post-PCI
CTFC is a continuous measurement assessing flow in the epicardial arteries.
Time frame: Echocardiography was performed 3-7 days after PCI
Echocardiographic index includes LVEF
RenJi Hospital
Other
Intracoronary Infusion of Alprostadil and Nitroglycerin With Targeted Perfusion Microcatheter in STEMI Patients With Coronary Slow Flow Phenomenon
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03508232
Cardiovascular Diseases, Heart Diseases
Edmonton, Alberta, Canada
View Trial DetailsNCT05461781
Arterial Occlusive Diseases, Cardiovascular Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT05705089
Cardiovascular Diseases, Embolism and Thrombosis
Tehran, Iran
View Trial DetailsNCT01538303
Cardiovascular Diseases, Heart Diseases
Eindhoven, North Brabant, Netherlands
View Trial Details